Characteristics of mental skills interventions in dance: a mixed methods systematic review protocol.

Introduction: Dancers are expected to navigate major challenges in their careers that might take a toll on their physical and mental health. To address underlying factors that might increase dancers' mental and physical health difficulties, research suggests the systematic use of techniques to build mental skills that can reduce risk factors and enhance protective factors against the challenges dancers encounter. However, existing mental skills training interventions in dance present a lack of consistency in design, content and duration, making it difficult to provide evidence-based recommendations.

Temporal progression of tau pathology and neuroinflammation in a rhesus monkey model of Alzheimer's disease.

Introduction: The understanding of the pathological events in Alzheimer's disease (AD) has advanced dramatically, but the successful translation from rodent models into efficient human therapies is still problematic.

Methods: To examine how tau pathology can develop in the primate brain, we injected 12 macaques with a dual tau mutation (P301L/S320F) into the entorhinal cortex (ERC). An investigation was performed using high-resolution microscopy, magnetic resonance imaging (MRI), positron emission tomography (PET), and fluid biomarkers to determine the temporal progression of the pathology 3 and 6 months after the injection.

Quality control data management with unity real-time in molecular virology.

Introduction: Quality control (QC) is one component of an overarching quality management system (QMS) that aims at assuring laboratory quality and patient safety. QC data must be acceptable prior to reporting patients' results. Traditionally, QC statistics, records, and corrective actions were tracked at the Johns Hopkins Molecular Virology Laboratory using Microsoft Excel.

A highly sensitive and quantitative assay for dystrophin protein using Single Molecule Count Technology.

Duchenne muscular dystrophy (DMD) is a genetic disease characterized by progressive muscle loss caused by mutations in dystrophin, resulting in decreased dystrophin levels. Dystrophin protein expression is a biomarker used to evaluate treatments that restore patient dystrophin levels. Currently, a semiquantitative assay using western blotting, which normalizes dystrophin expression to that of a control population, is used for regulatory filing.